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 Abstract 
Background: Chronic mast cell-mediated inflammation may contribute 
significantly towards the extensive tissue remodelling that is a feature of 
lungworm infection in ruminants. Understanding the factors that control tissue 
remodelling is a necessary step toward effective management and treatment of 
conditions that feature such pathology. Objective: We sought to define in a 
novel ovine model system, the cellular, immune and mast cell phenotypic 
events that occur following local lung challenge with a recombinant protein 
antigen, DvA-1, derived from the ruminant lungworm nematode, Dictyocaulus 
viviparus. Methods: Two spatially disparate lung segments in systemically 
sensitised sheep were challenged on three occasions with DvA-1 (3xDVA) and 
two further segments were challenged with saline (3xSAL). Two months after 
the third challenge, one of the two segments previously repeatedly challenged 
with DvA-1 was challenged again with DvA-1 (3xDVA:DVA) whilst the other was 
challenged with saline (3xDVA:SAL). A similar protocol was followed with the 
saline challenged segments (3xSAL:SAL & 3xSAL:DVA). Bronchoalveolar 
lavage fluid (BALF)(n=16) and tissue (n=3) were collected after the last 
challenge. Results: Cellular changes 24 h after the fourth challenge were 
characterised by an increase in the absolute numbers of neutrophils and 
eosinophils in BALF from 3xDVA:DVA and 3xSAL:DVA segments. Local 
antibody production was implied through increased levels of antibody in both 
3xDVA:DVA and 3xDVA:SAL segments, with the latter being unaffected by 
inflammation. Levels of active transforming growth factor beta-1 (TGF-β1) were 
significantly increased in 3xDVA:SAL segments and a trend towards an 
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increase was apparent in 3xDVA:DVA segments. Total TGF-β1 levels were 
significantly correlated with eosinophil counts in all except the 3xDVA:SAL 
segments. Such changes in the bronchoalveolar space were complemented by 
increased ratios of sheep mast cell proteinase-1 expressing cells and tryptase 
expressing cells, to toluidine blue positive cells in airways from 3xDVA:DVA 
segments. Conclusion: Mast cell phenotypic events occurring as a 
consequence of antigen challenge were limited to segments in which changes 
in BALF were characterised by neutrophil influx and increased local antibody 
production.  
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Introduction 
The pathology of patent lungworm (Dictyocaulus spp.) infection in ruminants is 
characterised by chronic catarrhal bronchitis and bronchiolitis, bronchial 
epithelial and mucous cell hyperplasia, increased peribronchiolar fibrous tissue 
and smooth muscle, and prominent eosinophil and mast cell infiltrates [1] 
[D.Collie pers. observation]. Understanding the factors that control the tissue 
remodelling processes that underlie the pathology would be of some relevance 
to human diseases such as asthma where pronounced airway wall remodelling 
occurs [2]. 
Mast cells are likely to play a fundamental role during tissue remodelling 
processes. In addition to the expression of matrix components (type VIII 
collagen alpha-1 chain) [3], mast cells contain an abundance of mediators 
(VEGF, FGF-2, PDGF, TGF-beta, NGF, IL-4, IL-8) that are at least potentially 
directly linked to neoangiogenesis, fibrinogenesis or re-epithelization processes. 
Central among such mediators is transforming growth factor-β1 (TGF-β1). This 
growth factor promotes ECM deposition by stimulating different collagen, 
elastin, fibronectin and proteoglycan genes to produce these ECM components 
[4-6]. TGF-β1 down-regulates proteinase genes and up-regulates proteinase 
inhibitor genes [7,8] and is also a potent immunosuppressive agent [9] and a 
potent chemoattractant under certain circumstances [10]. 
In addition, mast cells, through the release of TNF-α and other cytokines, can 
importantly influence the recruitment and/or function of additional effector cells 
such as eosinophils, neutrophils and lymphocytes [11]. 
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Mast cells are a phenotypically heterogeneous population with respect to tissue 
site, fixation properties, histochemical staining, biochemistry and functional 
activity. This heterogeneity is particularly reflected in the expression of mast cell 
granule proteases. In man, mast cells comprise a population that contains 
tryptase and chymase (MCTC) and one that contains only tryptase (MCT). The 
MCTC is found predominantly in skin and at subepithelial locations in the 
bronchial, nasal, and gastrointestinal mucosa, whereas the MCT is located 
predominantly in alveolar walls, gastrointestinal epithelium, and in the airway 
epithelium of patients with allergic disease.  
Similarly, sheep demonstrate mast cell heterogeneity. Using a polyclonal anti-
human tryptase antibody and a monoclonal antibody against sheep mast cell 
protease-I (SMCP-I), a chymase originally isolated from gastric mast cells, it is 
possible to demonstrate variation in immunoreactivity depending on the specific 
anatomical location. For example, SMCP-I is expressed in mast cells in the 
mucosa of the gut but not in the submucosa or adjacent muscularis [12]. 
Interestingly, in the lung, available evidence points to minimal SMCP and 
maximal tryptase immunoreactivity in mast cell populations surrounding the 
airways in normal sheep [12]. 
Dynamic flux in the relative proportions of phenotypically distinct mast cell 
populations may have important bearing on lung allergic responses. Indeed, in 
in murine rodents, the β-chymases, mouse mast cell protease-1 (mMCP-1) and 
rat mast cell protease –II (rMCP-II), which characterise mucosal mast cells in 
these species, are secreted systemically and into the gut lumen during 
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gastrointestinal allergic responses [13,14]. Further, transforming growth factor 
beta-1 (TGF-β1) has recently been implicated as a potential influence on such 
expression in the mucosal environment [15].  
In an effort to elucidate the mechanisms underlying mast cell mediated events 
in ovine allergic pulmonary disease we have developed a novel model based on 
systemic sensitisation with a recombinant antigen, DvA-1, from the bovine 
lungworm D. viviparus. DvA-1 is a retinoid-binding polyprotein and has similar 
sequence and deduced structural similarities to the ABA-1 allergen found in the 
respective human and porcine gastro-intestinal nematodes Ascaris lumbricoides 
and Ascaris suum [16,17]. We report here on the inflammatory and immune 
events that occur following local lung challenge with the same antigen. 
Materials and Methods 
Animals: Sixteen crossbred sheep (Shetland x and Merino x; 8 F and 8 MN) 
(bodyweight: 26 - 49 kg) were used in this study. Animals were treated with 
anthelminthic prior to entry into the study and were adjudged to be free from 
significant pulmonary disease on the basis of clinical examination.  
Production of recombinant DvA-1 polypeptide: Production of recombinant 
polypeptide was essentially as previously described [17]. Briefly, DNA encoding 
DvA-1 was amplified from plasmid pET 15b (Novagen, Madison, WI, USA) as a 
His-tag fusion protein and expressed in BL21 E. coli. Endotoxin levels, 
estimated by a kinetic turbidimetric limulus amoebocyte lysate (LAL) assay, did 
not exceed 0.8 EU (endotoxin units)/ml of DvA-1 stock (prepared to a 
concentration of 2mg/ml). 
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Sensitisation with DvA-1: Sheep were sensitised with DvA-1 adsorbed to 
AL(OH)3 gel (Alhydrogel, 20mg/ml; Accurate Chemical & Scientific Corporation, 
Westbury, NY) using 50µg DvA-1/500µl of AL(OH)3 in sterile water to 1ml, given 
intramuscularly on three occasions at biweekly intervals.  
Challenge: DvA-1 antigen was dissolved in 1ml saline to a final concentration of 
400 µg/ml. A nebulisation catheter (Trudell Medical International; London, 
Canada) placed in the biopsy channel of a fibreoptic bronchoscope was used to 
deliver the aerosolised solution to defined lung segments over a period of 
approximately 60 seconds. 
Anaesthesia and ventilation: Food was withheld for 12 hours prior to 
anaesthesia which was achieved by intravenous administration of a single bolus 
of thiopentone sodium (Intraval sodium; Rhône Mérieux Ltd.) at a dose rate of 
20 mg/kg bodyweight. Thereafter sheep were intubated and anaesthesia 
maintained using gaseous halothane (2-3 per cent) in oxygen and nitrous oxide. 
The sheep were placed in sternal recumbency in a large plexiglass whole body 
respirator (internal volume: 143 litres). The proximal end of the endotracheal 
tube was connected to the anaesthetic circuit through a connector in the wall of 
the box. Pressure in the box was varied by appropriate connection to a large 
bellows pump (Cuirass; Cape Warwick, Warwick, U.K.) which induced a 
sinusoidal tidal respiratory pattern, the rate and magnitude of which could be 
controlled by adjustment of the pump itself. The magnitude of pressure 
fluctuations were adjusted to maintain a tidal volume of 10ml/kg bodyweight. 
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Respiratory rate was adjusted to maintain end-tidal CO2 measurements in the 
range 4.5-5.5% (Oxicap Monitor Model 4700; Ohmeda, Louisville, CO, USA). 
Bronchoalveolar lavage: A flexible fibre optic bronchoscope (5.3mm OD)(Model 
FG-16X; Pentax U.K. Ltd.) was advanced and wedged in selected segmental 
bronchi. The subtended segments were lavaged by installation and withdrawal 
of two, 20ml aliquots of normal saline (0.9% NaCl solution). BALF was 
immediately placed on ice until subsequent analysis. 
Sample handling: Lavage fluid from each lung lobe was separated into 
supernatant and cells by centrifugation at 400g for 7min and the resultant cell 
pellets were resuspended in phosphate buffered saline (PBS) before differential 
cytology was determined. Supernatants were recentrifuged at 1,000 x g at 4oC 
for 20 min. The samples were stored at –70oC until analysis of immunoglobulin 
and TGF-β1 levels. 
Differential cytology: Cells were counted using a Neubauer haemocytometer 
and values expressed per millilitre BALF. Cytocentrifuge slides were prepared 
and stained using Leishmann’s stain for differential counts on 400 cells. Cells 
were classified as neutrophils, macrophages, eosinophils, lymphocytes or mast 
cells according to standard morphological criteria. Cells not classified in the 
aforementioned groups were recorded as ‘other’ cells. 
Measurement of TGF-β1 in BALF: TGF-β1 levels in BALF supernatant were 
measured using minor modifications of the procedure described by Abe et al 
(1994)[18]. Briefly, BALF supernatant was filtered through two layers of sterile 
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muslin and pre-spun in Vectaspin micro anopore filters (Whatman International 
Ltd., Maidstone, Kent) at 13000 rpm for 5 minutes to remove cell debris. The 
supernatant was then concentrated 5 times by means of Vivaspin 0.5ml 
concentrators (Vivascience Ltd. Gloucestershire, UK; 10,000 MW cut-off) used 
according to the manufacturers instructions. 
TGF-β1 is secreted in a latent form therefore acid activation is required to release 
active TGF-β1 from the latent complex. Relevant aliquots were acid activated by 
the addition of 5M HCl. Thereafter the samples were neutralised and submitted 
for assay. 
Mink lung epithelial cells (MLEC) stably transfected with an expression construct 
containing a truncated plasminogen activator inhibitor-1 (PAI-1) promoter fused to 
the firefly luciferase gene were used as the reporter system. TGF-β, through its 
induction of PAI-1 expression, causes dose-dependent increases in luciferase 
activity in this system [18]. MLECs were maintained at 37°C in Dulbecco’s 
Modified Eagles Medium (DMEM), 10% FBS containing penicillin-streptomycin, L-
glutamine and G418 (geneticin 200 µg/ml) (Life Technologies, Cambridge, UK). 
The sample assay involved removing and replacing cell medium with 100µl BALF 
supernatant. Assay plates were incubated overnight. Thereafter the cells were 
washed and lysed and the lysate added to opaque-walled 96-well plates (Dynex 
Technologies, Middlesex, UK). Samples were read in a Reporter™ microplate 
luminometer (Turner Designs Inc., Sunnyvale, CA, USA) using a luciferase 
substrate for a single flash reaction. Samples were read against a standard curve 
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prepared using appropriate dilutions of human recombinant TGF-β1 (R&D 
Systems Europe Ltd, Oxon, UK). 
Measurement of BALF immunoglobulin levels: DvA-1 specific IgG levels were 
measured by standard ELISA. Ninety-six well round-bottom polyvinyl chloride 
microtitation plates (Dynex Immulon 1B)(Dynex Technologies, Middlesex, UK) 
were coated with 50µl of rDvA-1 antigen  (2 µg/ml in 50mM NaHCO3 (pH 9.6)) and 
incubated overnight at 4°C.  After washing twice with PBS/0.05% tween20, 
blocking buffer (2% goat serum in PBS/0.05% tween20) was added to each well 
and incubated for 30 minutes at 20°C. After washing the plates 3 times 50µl of 
the sample, diluted in PBS/0.05% tween 80, was added. After incubating for 1 
hour at 20°C the plates were washed 6 times. 50 µl mouse anti-sheep IgG 
monoclonal antibody (VPM6)[19] diluted 1:10 in PBS/0.05% Tween20 was 
added. After incubation for 1 hour at 20°C the plates were washed 6 times. 50 µl 
of the second antibody (biotinylated goat anti-mouse IgG; DAKO, Glostrup, 
Denmark) diluted in PBS/0.05% Tween20 were added.  After incubating for 1 
hour at 20°C the plates were washed 6 times. 50 µl of streptavidin peroxidase 
diluted 1/2000 in PBS/0.05% Tween20 were added to each well and incubated 
for 1 hour at 20°C. 3,3’,5,5’-tetramethylbenzidine (TMB) (Sigma, Poole, UK) was 
used as substrate and chromogen for horseradish peroxidase. Colour 
development was stopped by adding 50 µl of 0.5M H2SO4 to each well.  
Plates were read at OD of 450 nm by use of an automated microtitration plate 
reader (EL311, BioTek Instruments, VT, USA). For a given BALF supernatant 
sample four dilutions were made. The resultant ODs were multiplied by the 
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respective dilution factors to give unit measurements and the level of 
immunoglobulin was taken as the average of these four measurements. 
Tissue handling: Lung tissue was fixed by airway instillation of 10% neutral 
buffered formalin (pH 7.0) at an inflation pressure of 2.5 to 3.0 kPa for 3 days. 
Following fixation, three tissue blocks were sampled from each lung segment 
and routinely processed and embedded in paraffin. Serial 4 µm sections were 
cut from the tissue blocks and one set stained with toluidine blue. Remaining 
sections were mounted on polylysine coated slides (BDH Laboratory supplies, 
Poole, England) for immunohistochemistry. 
Immunohistochemistry: Endogenous peroxidase was inactivated by pre-treating 
sections with periodic acid and sodium borohydride [20]. Sections were treated 
with trypsin (0.1% trypsin in 0.1% CaCl2 (pH 7.8)) for 30 min at RT to unmask 
antigenic sites and thereafter incubated in 4% bovine serum albumin (Sigma, 
Poole, UK) in PBS for 30 min at RT. For immunohistochemical localisation of 
SMCP-I, rat mAb anti-SMCP (diluted in 4% BSA/PBS) was added for 1 hr, prior 
to washing three times in PBS. A biotinylated rabbit anti-rat IgG (diluted in 4% 
BSA/PBS) was applied for 30 min at RT. The section was washed three times in 
PBS and Vectastain® ABC reagent (Vector Laboratories, Burlingame, CA, 
USA) applied for 30 min. After a final wash, peroxidase activity was revealed 
with 3,3’-diaminobenzidine (DAB). Control sections were stained using a 
matched rat IgG2a isotype at 10µg/ml. For localisation of tryptase, rabbit anti-
human tryptase IgG (20 µg/ml) [12,21], biotinylated goat anti-rabbit antibodies 
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(Vector Laboratories, Burlingame, CA, USA) and normal rabbit IgG were 
employed as primary, secondary and source of control antibodies respectively.  
Counting technique: Three airways were identified on each section and their 
location and identity recorded schematically on simple diagrams. The length of 
the basement membrane of each airway was measured and recorded using a 
computerised image analysis facility (Quantimet Q500C, Leica, UK). Thereafter 
the number of stained positive cells in an area of interest defined internally by 
the airway epithelium and externally by the outer cartilaginous border of the 
airways of interest were counted and expressed as cells/mm basement 
membrane. Results from differentially treated segments were collated and the 
mean values reported. 
Experimental design: Two weeks after the last intramuscular injection of DvA-
1:ALUM four spatially disparate lung segments were selected on bronchoscopic 
examination and their position carefully mapped. The segments were randomly 
assigned to one of two challenge protocols, namely repeated (3x) weekly 
aerosol challenge with DvA-1 (3xDVA) or repeated (3x) weekly aerosol 
challenge with saline (3xSAL)(Figure 1). Two weeks after the third challenge, 
BALF was collected from one segment randomly selected from the pair 
subjected to each of the challenge protocols. Two months after the third 
challenge, one of the two segments previously repeatedly challenged with DvA-
1 was challenged again with DvA-1 whilst the other was challenged with saline. 
Similarly, one of the two segments previously repeatedly challenged with saline 
was challenged again with saline whilst the other was challenged with DvA-1. 
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Twenty-four hours after the last challenge, sheep were re-anaesthetised and 
BALF collected from each of the four treated segments (3xSAL:SAL; 
3xSAL:DVA; 3xDVA:SAL; 3xDVA:DVA). Three sheep were killed 24 hr after the 
last challenge to provide tissue for histopathological and immunohistochemical 
analysis. 
Data analysis: Within sheep, between segment comparisons were assessed 
using Freidman non-parametric tests for related variables. Where significant 
changes were identified, further analysis was conducted using Wilcoxon signed 
rank tests to compare between specific segments. Degrees of association 
between measurements were assessed using the Spearman rank correlation 
coefficient (rs). 
Results 
BALF cytology: Two weeks after the third segmental challenge, BALF cellular 
parameters did not differ between 3xSAL and 3xDVA segments (data not 
shown). Twenty four hours after the final segmental challenge, Freidman tests 
revealed significant differences between segments with respect to total cell 
counts, comprising changes in the absolute numbers of neutrophils and 
eosinophils (table 1). BALF from 3xSAL:DVA and 3xDVA:DVA segments 
contained significantly more cells than 3xSAL:SAL segments (p<0.05) with 
neutrophils the predominant cell type involved (p<0.01)(figure 2a). A significant 
increase in the number of eosinophils in 3xSAL:DVA, 3xDVA:SAL and 
3xDVA:DVA segments (p<0.01, p<0.05 and p<0.01 respectively) was noted 
(figure 2b). 
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TGF-β1 levels in BALF: There were no significant differences between 
segments with respect to levels of total TGF-β1 in BALF twenty four hours after 
the final segmental challenge. However, there were significantly increased 
levels of active TGF-β1 in the 3xDVA:SAL segments (p<0.05) and a trend 
towards increased levels in the 3xDVA:DVA segments (p=0.08) relative to 
levels in the 3xSAL:SAL segments. Levels of total and active TGF-β1 are 
depicted in Figure 3. Total TGF-β1 levels were significantly correlated with 
absolute numbers of eosinophils in 3xSAL:SAL, 3xSAL:DVA and 3xDVA:DVA 
segments twenty four hours after the final segmental challenge (rs = 0.580, 
0.588 and 0.627 and p< 0.05, p<0.02 and p<0.02 respectively). The relationship 
between absolute numbers of eosinophils and total TGF-β1 in BALF from 
3xDVA:DVA segments is depicted in Figure 4. There were no other significant 
associations between cellular and immune parameters and levels of total or 
active TGF-β1 in BALF twenty four hours after challenge. 
BALF Immunoglobulins: Levels of anti-DvA-1 specific IgG in BALF from 
3xDVA:DVA and 3xDVA:SAL segments were significantly increased relative to 
levels in the 3xSAL:SAL segments (p<0.01)(Figure 5). 
Histochemical analysis: The number of toluidine blue-stained cells expressed 
per millimetre airway basement membrane in 3xSAL:DVA, 3xDVA:SAL and 
3xDVA:DVA segments did not differ significantly from 3xSAL:SAL segments 
twenty four hours after the final challenge (Table 2). 
Immunohistochemical analysis: Low and highly variable numbers of SMCP-1 
immunoreactive cells precluded statistical analysis based on absolute cell 
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numbers. The numbers of SMCP-1 and tryptase immunoreactive cells were 
therefore expressed as ratios of the number of toluidine blue-stained cells 
counted in the same airways. Summary data relating to absolute cell counts is 
shown in table 2. Similar numbers of tryptase positive and toluidine blue-stained 
cells were identified in airways from 3xSAL:SAL, 3xSAL:DVA and 3xDVA:SAL 
segments 24hr after the final challenge (tryptase:toluidine blue ratio 0.93±0.46, 
0.87±0.6 and 1.14±0.96 (mean±SD) respectively), however approximately twice 
as many tryptase positive cells as toluidine blue stained cells were identified in 
the 3xDVA:DVA segments at this time point (2.04±1.64). Similarly an increased 
ratio of SMCP-1 positive cells relative to toluidine blue stained cells was 
identified in airways from 3xDVA:DVA segments at 24hr (SMCP-1:toluidine blue 
ratio 0.64±0.81) when compared with the same ratio in other segments 
(0.23±0.33, 0.26±0.26 and 0.29±0.46 (mean+SD) in airways from 3xSAL:SAL, 
3xSAL:DVA and 3xDVA:SAL segments respectively) In both instances the 
increased ratios were significant when compared with ratios in 3xSAL:SAL 
segments (p<0.05)(Figure 6).  
Virtually all cells (>95%) identified by toluidine blue or immunohistochemical 
staining were located between the epithelial basement membrane and the outer 
cartilaginous border i.e. intraepithelial cells were rarely identified. Cells were 
commonly identified surrounding submucosal glands or within and around 
smooth muscle bundles.  
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Discussion 
Lung nematode infection is characterised by prominent mastocytosis. 
Crosslinking of pre-bound specific anti-parasite IgE antibody on the surface of 
these cells is believed to result in degranulation with the release of a variety of 
mediators which have the collective effect of increasing vascular permeability, 
causing local vasodilation, bronchial and visceral smooth muscle contraction 
and local inflammation. Although such effects will contribute towards nematode 
expulsion, chronic mast cell-mediated inflammation may contribute significantly 
towards the extensive tissue remodelling that is a feature of lungworm infection 
in ruminants [1,22]. We sought to develop a model system appropriate to the 
investigation of the role of mast cells in this regard.  
 
Several factors contributed towards our adoption of a segmental, rather than 
whole lung, approach to challenge. Wherein responses can be considered local 
such an approach allows each animal to serve as its own control, thus reducing 
the extent of inter-animal variability associated with whole lung studies. 
Responses are limited to defined areas of the lung and as such are associated 
with no discernible clinical effect. Segmental approaches have hitherto proved 
valuable in the context of defining, at functional, cellular and immune levels, the 
local lung response to antigen challenge in both experimental animals and in 
man [23-30].  
 
Sensitisation with DvA-1 in ALUM resulted in a vigorous systemic antibody 
response characterised by increased antigen-specific IgG. 
 17 
 
Cellular response to antigen challenge was characterised by a neutrophil 
inflammatory cell infiltrate at 24hr. Although this is consistent with data in dogs 
in response to particulate [31] and soluble [32] antigen, and in healthy human 
subjects [33] and subjects with hypersensitivity pneumonitis [34] in response to 
antigen, some comment is appropriate in relation to the possible influence of 
endotoxin in contributing to this response. Indeed it has been demonstrated that 
endotoxin, either sourced to the antigen preparation [35] or arising as a specific 
consequence of the bronchoscopy procedure [36], may contribute to BAL-
induced lung inflammation. A total of 0.8 EU was delivered to each segment 
during the challenge procedures, an amount considerably less than the 12.5 
EU/ml suggested as being more likely to alter the cellular inflammatory 
response of human subjects to allergen [35]. Although it is acknowledged that 
species vary considerably in their response to endotoxin [37], in defence of this 
particular inter-species comparison, it is of note that sheep do appear to share a 
similar endotoxin sensitivity to man [38]. Thus it is considered unlikely that 
endotoxin contamination of the antigen preparation made a significant 
contribution to the observed neutrophilic influx. Further, the adopted segmental 
approach controls for the possibility of a lung neutrophilic response arising as a 
consequence of the bronchoscopic procedure itself.  
 
All segments with an immediate or long-term history of exposure to DvA-1 had 
increased numbers of eosinophils in BALF 24hr after challenge. Although the 
effect was most striking in segments with concomitant neutrophilic inflammation, 
 18 
numbers were in addition increased in the 3xDvA:SAL segment relative to the 
3xSAL:SAL segment.  The median absolute eosinophil count from 3xSAL:SAL 
segments was 166 cells/ml whereas the median count from 3xDVA:DVA 
segments was 1.7 x 103 cells/ml, representing 0.2 and 0.8% of the total cell 
count respectively. By way of comparison, in Ascaris suum allergic sheep the 
whole lung response to inhaled allergen is characterised by less than 0.5% of 
total cells being identified as eosinophils at the 24hr time point after challenge 
[39]. Overall, such cell counts are modest both in relation to the eosinophilic 
response seen during natural lungworm infection [22,40], and in comparison 
with changes seen in allergic human subjects in response to segmental antigen 
challenge. In the latter regard, in ragweed-allergic asthmatics, absolute 
eosinophil counts increased from a mean of 0.49x104/ml BALF (3.7% of total) to 
59.0 x 104/ml (~56%) at 24hr after challenge with antigen [22].  
 
We examined cellular and immune changes at 24h after challenge.  In an 
analogous canine model, the numbers of eosinophils in BALF were significantly 
raised 4 days after challenge with the relevant antigen [41,42]. Although 
preliminary data suggests similar eosinophil kinetics in the present model (D. 
Collie, unpublished observation), further time-course evaluation after antigen 
challenge will be necessary to fully define such events post-challenge.  
 
The present study demonstrates that antigen specific IgG is present in BALF of 
segments with a prior history of exposure to a recombinant antigen derived from 
D.viviparus. Indeed the disassociation of antibody levels in BALF from 
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concomitant inflammation (comparing 3xDVA:DVA and 3xDVA:SAL segments) 
suggests that antibody is locally derived rather than a reflection of a serum 
response. These findings are consistent with extensive studies in dogs [43-48]. 
 
Our findings demonstrate a significant increase in the ratio of SMCP-1 and 
tryptase expressing cells, to toluidine blue stained cells in airways from 
3xDvA:DvA segments relative to 3xSAL:SAL segments. It is of some interest 
that the tryptase:toluidine blue ratio was close to 1.0 in all bar the 3xDvA:DvA 
segment whereas the SMCP:toluidine blue ratio was much lower (~0.25) in 
these segments. Further immunohistochemical analysis using dual staining is 
required to ascertain firstly whether these separate proteases are contained 
within the same population of cells and secondly, whether, as is the case in 
human bronchi [49], differences exist in relation to protease expression and 
anatomic sublocation in the airway wall.  
 
Regardless of the specific roles that these proteases play in our model system, 
clearly there would appear to be a requirement for both inflammatory and local 
lung immune components in dictating the conditions necessary for their 
expression. The twin observations that the pleiotropic cytokine, transforming 
growth factor beta 1 (TGF-β1), has been shown to play an important role in vitro 
in promoting the expression of mMCP-1 in cultured mBMMC [15] and is raised 
24 hr following segmental bronchoprovocation of atopic asthmatics with allergen 
[33], prompted our measurement of this cytokine in this study. 
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We were able to demonstrate an increase in the levels of active TGF-β1 in 
BALF 24h after challenge in 3xDVA:SAL segments and a trend towards an 
increase in 3xDVA:DVA segments. The implication would be that lung 
segments chronically challenged with DvA-1 and which are uniquely 
characterised by eosinophilia and increased levels of local antibody production 
have in place mechanisms which are responsible for activating TGF-β1. 
Principal mechanisms include the cleavage [50] or conformational alteration of 
latency associated peptide (LAP)[51,52], which noncovalently associates with 
TGF-β and prevents receptor binding. It remains to be established whether 
TGF-β1 is responsible for the increased expression of SMCP-1 in 3xDVA:DVA 
segments. However, preliminary in vitro studies of sheep BMMC suggest that 
this cytokine does upregulate expression of SMCP-1 (Huntley, JF and Miller 
HRP, unpublished). 
 
Eosinophils appear to be a primary source of TGF β1 mRNA [53,54] in asthma, 
a finding that adds credence to our observed association between the number 
of eosinophils and the levels of total TGF-β1 in BALF in all bar the 3xDVA:SAL 
segment. This latter segment was characterised by a significant increase in 
active TGF-β1 and such activation of total TGF-β1 may have contributed to the 
observed lack of association with eosinophil numbers in this segment. 
 
In conclusion, we have demonstrated that repeated local lung challenge of 
systemically sensitised sheep with a recombinant protein derived from the 
lungworm spp. Dictoyocaulus viviparus leads to the development of local 
 21 
antibody production. Cellular changes 24 hr after the fourth challenge are 
characterised by an increase in the absolute numbers of neutrophils and 
eosinophils and are complemented by increased ratios of SMCP-1 expressing 
cells and tryptase expressing cells to toluidine blue positive cells in airways.  
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